Garrison Point Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Garrison Point Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$933K	Sell	15,383 -6	-0%	-$350	0.43%	65
2025 Q4	$830K	Buy	15,389 +638	+4%	+$30.7K	0.37%	69
2025 Q3	$665K	Buy	14,751 +745	+5%	+$34.8K	0.28%	89
2025 Q2	$648K	Sell	14,006 -2,525	-15%	-$124K	0.3%	87
2025 Q1	$1.01M	Buy	16,531 +200	+1%	+$11.7K	0.49%	57
2024 Q4	$924K	Hold	16,331	–	–	0.44%	59
2024 Q3	$845K	Sell	16,331 -535	-3%	-$25.1K	0.52%	57
2024 Q2	$700K	Sell	16,866 -604	-3%	-$27K	0.46%	66
2024 Q1	$947K	Sell	17,470 -400	-2%	-$20.4K	0.61%	53
2023 Q4	$917K	Sell	17,870 -406	-2%	-$21.3K	0.65%	48
2023 Q3	$1.06M	Sell	18,276 -204	-1%	-$12.5K	0.82%	37
2023 Q2	$1.18M	Sell	18,480 -130	-0.7%	-$8.72K	0.85%	34
2023 Q1	$1.29M	Sell	18,610 -26	-0.1%	-$1.83K	0.97%	29
2022 Q4	$1.34M	Hold	18,636	–	–	1.1%	28
2022 Q3	$1.32M	Hold	18,636	–	–	1.18%	26
2022 Q2	$1.44M	Buy	18,636 +100	+0.5%	+$7.62K	1.19%	25
2022 Q1	$1.35M	Hold	18,536	–	–	0.95%	30
2021 Q4	$1.16M	Hold	18,536	–	–	0.77%	43
2021 Q3	$1.1M	Buy	18,536 +120	+0.7%	+$7.9K	0.8%	39
2021 Q2	$1.23M	Buy	18,416 +106	+0.6%	+$6.91K	0.89%	34
2021 Q1	$1.16M	Sell	18,310 -70	-0.4%	-$4.36K	0.9%	37
2020 Q4	$1.14M	Buy	18,380 +485	+3%	+$29.8K	0.92%	32
2020 Q3	$1.08M	Sell	17,895 -100	-0.6%	-$6.02K	0.98%	31
2020 Q2	$1.06M	Sell	17,995 -478	-3%	-$28.6K	1.05%	32
2020 Q1	$1.03M	Sell	18,473 -469	-2%	-$28.7K	1.26%	30
2019 Q4	$1.22M	Buy	18,942 +6,565	+53%	+$376K	1.11%	34
2019 Q3	$628K	Hold	12,377	–	–	0.62%	58
2019 Q2	$561K	Hold	12,377	–	–	0.56%	65
2019 Q1	$591K	Hold	12,377	–	–	0.62%	57
2018 Q4	$643K	Buy	+12,377	New	+$665K	0.79%	49

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Garrison Point Advisors's BMY Position: Q1 2026 in Review

Garrison Point Advisors reduced its Bristol-Myers Squibb (BMY) stake by 0.04% in Q1 2026, selling an estimated $350 and leaving 15,383 shares worth $933K. The position accounts for 0.43% of the portfolio, ranked #65.

Garrison Point Advisors first reported a position in BMY in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.44M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Garrison Point Advisors held 15,383 shares of Bristol-Myers Squibb worth $933K as of Q1 2026.
Garrison Point Advisors sold 6 Bristol-Myers Squibb shares in Q1 2026, an estimated $350.
Bristol-Myers Squibb made up 0.43% of Garrison Point Advisors's portfolio in Q1 2026, its #65 holding.
Garrison Point Advisors first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 30 quarters since.
Garrison Point Advisors's Bristol-Myers Squibb position peaked at $1.44M in Q2 2022.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Garrison Point Advisors's 13F filing for Q1 2026, filed 13 May 2026.